In the field of lung cancer, recent reports showed the certain clinical efficacy of lung cancer with programmed cell death-1 (PD-1) signal blockade with monoclonal anti-PD-1 antibody as well as ipilimumab [13]. This evidence concerns the gene PDCD1 and lung carcinoma.